Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Window Study of Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases

NCT03498612 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT03498612
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03498612 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Window Study of Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases
Lead sponsor
University of Washington
Phase
Phase 2
Overall status
Terminated
Start date
July 9, 2018
Completion date
August 29, 2024
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

follicular lymphoma, indolent b-cell non-hodgkin lymphoma, marginal zone lymphoma